A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch

Overview

The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.

Full Title of Study: “A Multicentre Prospective Study in Patients Undergoing Ventral Hernia Repair by Open Approach With Intraperitoneal Positioning Using Parietex™ Composite Ventral Patch – Panacea Study.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2016

Detailed Description

Prospective, multicenter, multinational non-comparative study. Primary Endpoint: Primary hernia recurrence* rate at 24 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and by ultrasonography. Secondary Endpoints: Primary hernia recurrence* rate at 1, 6 and 12 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and confirmed by ultrasonography. (*Recurrence is defined as a clinically manifested bulge or a protrusion exacerbated by a Valsalva maneuver.) Safety Parameters: Deep and superficial infection (A Surgical Site Infection (SSI) will be defined in the study according to the Centers for Disease Control and Prevention (CDC) criteria for diagnosis of SSI). Pain / Chronic pain Other post-operative complications (complications related to visceral adhesions, Ileus, seroma, hematoma…) Analgesics consumption Risk factors (severity and treatment) Efficacy Parameters: Recurrence of primary ventral hernia Operative time Time of the mesh positioning Length of Hospital Stay Ease of use (Mesh handling and manipulability, comfort of use …) Return to daily activities/ work Patient satisfaction Patient comfort (Carolina's™ Comfort scale (CCS) – QoL questionnaire) Visit Schedule: Baseline visit (Preoperative) & Operative/Discharge visit Post-Op: Phone call Day 10 1 month 6 months 12 months 24 months Duration: 12 months recruitment and 24 months follow-up Up to 12 sites in Europe and the United States will be included in this study

Interventions

  • Device: PARIETEX™ Composite Ventral Patch
    • PARIETEX™ Composite Ventral Patch for ventral hernia repair

Arms, Groups and Cohorts

  • PARIETEX™ Composite Ventral Patch
    • PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning

Clinical Trial Outcome Measures

Primary Measures

  • Primary Hernia Recurrence Rate at 24 Month Follow-up.
    • Time Frame: 24 month follow-up
    • The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.

Secondary Measures

  • Recurrence Rate at 1, 6 and 12 Month Follow-up
    • Time Frame: 1, 6 and 12 month follow-up.
    • The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit.

Participating in This Clinical Trial

Inclusion Criteria

  • All patients (adult ≥ 18 years) at participating centres undergoing primary ventral hernia repair with the device by open approach – Signed informed consent form by the patient or the legally authorized representative – Intraoperative inclusion criteria :Size of the defect: ≤ 4 cm Exclusion Criteria:

  • Emergency procedure – Current participation in other trials – History of previous hernia at the same location. – Pregnant women: Women who are known or suspected to be pregnant, or who are planning to become pregnant during the study follow-up period – Patient < 18 years – BMI > 35 – ASA score ≥ 4 – The investigator determined that the patient will not be able to comply with the required follow-up visits

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medtronic – MITG
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Frederik Berrevoet, MD, Principal Investigator, University Hospital Ghent (Belgium)
    • Lars N Jørgensen, MD, Principal Investigator, Bispebjerg Hospital, University of Copenhagen (Denmark)
    • Carl Doerhoff, MD, Principal Investigator, Surgicare of MO (United States)
    • Steven Hopson, MD, Principal Investigator, Hernia Centers of Excellence, VA (United States)
    • Eric KULLMAN, MD, Principal Investigator, Medicinskt Centrum i Linköping (Sweden)
    • Marco G MUZI, MD, Principal Investigator, Department of Surgery, University Hospital Tor Vergata, Roma (Italy)
    • Simon NIENHUIJS, MD, Principal Investigator, Catharina Ziekenhuis, EJ EINDHOVEN (The Netherlands)
    • Filip E Muysoms, MD, Principal Investigator, Algemene Heelkunde, AZ Maria Middelares Ghent (Belgium)
    • Tim Tollens, MD, Principal Investigator, Imelda Hospital, Bonheiden (Belgium)
    • Karl Leblanc, MD, Principal Investigator, Our Lady of the Lake Regional Medical Center, LA (United States)
    • Mark Schwartz, MD, Principal Investigator, Monmouth Medical Center, NJ (United States)
    • Vic Velanovich, MD, Principal Investigator, University of South Florida (United States)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.